GlassScriptPhysician profile
Tsu-Hon Wang
NPI 1457369498
$21,179.86
in general payments reported to CMS, 2019-2025
35 companies · $3,869 in 2025
The $3,869 reported for 2025 was more than what 89% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $989 · 2020: $650 · 2021: $1,381 · 2022: $2,271 · 2023: $7,819 · 2024: $4,201 · 2025: $3,869.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $11K · Consulting Fee: $3,575 · Travel and Lodging: $862 · Education: $72.21.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $11,380.39 |
| Consulting Fee | $3,575.00 |
| Travel and Lodging | $861.87 |
| Education | $72.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $4,619.93 | 2019-2025 | Rinvoq, Skyrizi, Creon |
| E.R. Squibb & Sons, L.L.C. | $3,986.11 | 2021-2023 | Zeposia |
| Janssen Biotech, INC. | $1,587.09 | 2019-2025 | Stelara, Tremfya, Simponi Aria |
| Celgene Corporation | $1,538.78 | 2021-2024 | Zeposia |
| Gilead Sciences, INC. | $1,421.65 | 2021-2025 | Epclusa, Livdelzi |
| Takeda Pharmaceuticals U.S.A., INC. | $1,147.43 | 2019-2025 | Entyvio, Eohilia, Gattex |
| Genzyme Corporation | $1,083.19 | 2022-2025 | |
| Lilly USA, LLC | $890.99 | 2024-2025 | Omvoh |
| Madrigal Pharmaceuticals | $767.84 | 2024-2025 | Rezdiffra, Resmetirom |
| Ardelyx, INC. | $607.77 | 2024-2025 | Ibsrela |
| Regeneron Healthcare Solutions, INC. | $502.05 | 2022-2025 | Dupixent |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $478.80 | 2019-2025 | Xifaxan, Plenvu, Trulance |
| Pfizer INC. | $414.39 | 2019-2025 | |
| Phathom Pharmaceuticals, INC. | $322.01 | 2023-2025 | Voquezna |
| Janssen Scientific Affairs, LLC | $240.00 | 2019-2021 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ipsen Biopharmaceuticals, INC | $218.88 | 2025 | Iqirvo |
| Daiichi Sankyo INC. | $204.19 | 2019-2020 | |
| Organon LLC | $166.11 | 2022-2025 | Renflexis, Hadlima |
| Steris Corporation | $164.58 | 2025 | |
| Regeneron Pharmaceuticals, INC. | $149.61 | 2024 | Dupixent |
| Qol Medical, LLC | $106.94 | 2023-2024 | Sucraid, Sucraid |
| Boehringer Ingelheim Pharmaceuticals, INC. | $70.30 | 2023-2024 | Cyltezo |
| Ironwood Pharmaceuticals, INC | $68.21 | 2019-2020 | |
| Vivus LLC | $60.95 | 2019 | |
| Braintree Laboratories, INC. | $58.81 | 2019-2021 | |
| Celltrion USA INC. | $56.10 | 2024 | Zymfentra |
| Boston Scientific Corporation | $48.24 | 2021 | |
| Medtronic, INC. | $30.06 | 2022-2024 | Gi Genius |
| Echosens North America, INC. | $28.34 | 2024-2025 | Fibroscan, Fibroscan |
| Mauna Kea Technologies, INC. | $26.95 | 2022 | |
| Intercept Pharmaceuticals, INC. | $26.89 | 2020-2023 | Ocaliva |
| Allergan, INC. | $26.15 | 2019 | |
| Exact Sciences Corporation | $23.82 | 2025 | Cologuard Collection Kit |
| Capsovision, INC. | $20.59 | 2024 | Capsocam Plus |
| Nestle Healthcare Nutrition INC. | $16.11 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tsu-Hon Wang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.